Cybin provides corporate update on upcoming clinical milestones

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones. “we are making rapid advancements in our two lead clinical programs – cyb003, our proprietary deuterated psilocin program in development for the.
CYBN Ratings Summary
CYBN Quant Ranking